Global Journals ${\mathbin{\ensuremath{\mathbb A}}} T_{\ensuremath{\mathbb F}} X$ Journal
Kaleidoscope^{TM}

Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. *Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.*

Moringa Oleifera Seed Protein Hydrolysates Inhibit Haemoglobin Glycosylation and ?-Glucosidase Activity in-vitro Augustine Olusegun Olusola¹ and Oluwafemi Emmanuel Ekun² ¹ Adekunle Ajasin University

Received: 12 December 2018 Accepted: 4 January 2019 Published: 15 January 2019

7 Abstract

5

In recent times, the biological activities of enzymatic digests of plant and animal proteins have 8 been investigated and have been shown to exhibit multidirectional effects against key enzymes 9 involved in the pathophysiology of a number of diseases. The present study evaluated the 10 inhibitory effects of M.oleifera seed protein hydrolysates on haemoglobin glycosylation and 11 ?-glucosidase. Proteins were hydrolyzed using the enzymes pepsin, trypsin, papain and 12 chymotrypsin. The resulting hydrolysates were evaluated for inhibitory activities against 13 non-enzymatic haemoglobin glycosylation as well as ?- glucosidase. Peptic and chymotrypsin 14 hydrolysates demonstrated the best inhibitory effects against hemoglobin glycosylation, while 15 chymotryptic and tryptic hydrolysates had better ?-glucosidase inhibitory activities. Kinetic 16 data showed that the hydrolysates inhibited ?-glucosidase inhibitory effects by different 17 mechanisms, such tryptic and chymotrypsin hydrolysates indicated a competitive mode of 18 inhibition while papain and pepsin hydrolysates displayed mixed inhibition of ?-glucosidase. 19 These results suggest that M. leifera seed proteins contain peptides that can be harnessed to 20 formulate peptides which could serve as novel alternatives to current therapies in the 21 management of diabetes mellitus. 22

23

Index terms— M.oleifera, hydrolysates, pepsin, trypsin, papain, chymotrypsin, hemoglobin, ?-glucosidase, diabetes mellitus.

²⁶ 1 Introduction

eptide products of plant and animal proteins have in recent times have been exploited for therapeutic purposes (Olusola et al., 2018). Peptides of therapeutic value have been utilized in the treatment and management of a variety of disorders (Lien and Lowman, 2004). For the most part, emphasis has been placed on the use of peptides and protein hydrolysate preparations as possible alternatives in the management of cardiovascular diseases such as hypertension (Arise et al., 2016 a) and diabetes mellitus (Arise et al., 2016 b , Olusola and Ekun, 2019). One plant whose proteins encode potentially bioactive peptides is M. oleifera.

Moringa oleifera is naturalized in India, especially in the Western & Himalayan regions. It is also found in 33 34 the tropical regions of Africa as well as the Middle East (Madubuike et al., 2015). Mune-Mune et al., ??2016) 35 reported that M. oleifera seeds have a relatively high protein content, over 30%, making it an excellent source 36 of potentially therapeutic peptide products when subjected to enzymatic hydrolysis. Globulins and albumins constitute the major portion of Moringa oleifera seeds (Baptista et al., 2017), and amino acid analysis reveals 37 that it contains high proportion of basic and acidic amino acids, moderate amount of most hydrophobic amino 38 acids, but limiting in sulfurcontaining amino acids such as methionine and cysteine (Okereke and Akaninwor, 39 2013). Parts of the plant such as its leaves, seeds and roots have been evaluated for their health promoting 40 benefits which include hypoglycemic effects (Villarruel-López et al., 2018) antimicrobial activity (Bukar et al., 41 2010), antioxidative potentials (Wright et al., 2017) among other properties. 42

7 I. ISOLATION OF MORINGA OLEIFERA SEED PROTEINS

Diabetes mellitus is a metabolic disorder occurring as a result of disturbances in insulin function. It is 43 characterized by severe hyperglycemia and leads to a plethora of derangements in the metabolism of carbohydrate, 44 proteins and lipids (Arise et al., 2016 b). These ultimately cause damage to organs, such as liver, kidney, retina, 45 as the disease progresses. One of the adverse effects of elevated blood glucose is the formation of advanced glycated 46 end products, and this occurs when blood glucose forms non-enzymatic covalent adducts with protein and lipids 47 in plasma. (Ramasamy et al., 2005). These glycated products may set the stage for the onset of generation of 48 reactive oxygen species; activating a number of proinflammatory pathways causing impaired cellular function, 49 and these are thought to occur by signal transduction processes mediated by the receptor for advanced glycated 50 end-products (RAGE) play key roles in pathogenesis the diabetic cataracts, diabetic neuropathy and nephropathy 51 (Singh et al., 2014). 52 Current therapeutic approaches are aimed at controlling glucose levels by slowing its rate of release into the 53

blood stream by inhibiting glucoside cleavage enzymes such as ?-amylase and ?-glucosidase; increasing insulin 54 sensitivity by altering the activities of incretin degrading enzymes such as dipeptidylpeptidase (iv) in combination 55 with lifestyle changes (Katzung et al., 2012). However, these chemotherapeutic approaches give rise to certain 56 untoward side effects such as gastrointestinal discomfort and renal damage. Also, many of these drugs, owing to 57 58 their high cost of procurement, increase economic burden on patients as well as their relatives . Hence, the search 59 for newer, safe and cost-effective alternatives in the management of diabetes mellitus cannot be overemphasized, 60 and recently attention has turned to newer sources such as peptides and hydrolysate preparations (Olusola and 61 Ekun, 2019).

There have been reports about several biofunctional properties of various parts of the M. oleifera plants (??nwar et al., 2007). Previous work had demonstrated that hydrolysates obtained from its seed proteins possess ?-amylase inhibitory activities (Garza et al., 2017, Olusola et al., 2018). Hence, this study aims to evaluate the inhibitory activities of M. oleifera seed protein hydrolysates on hemoglobin glycosylation and ?-glucosidase to

66 further justify their anti-diabetic potentials.

67 **2** II.

⁶⁸ 3 Materials and Methods

⁶⁹ 4 a) Materials

⁷⁰ 5 i. Collection of Moringa oleifera seeds

Moringa oleifera seeds were bought from stores in Ikere-Ekiti, Ekiti State, Nigeria, and authenticated by the
 Department of Plant Science and Biotechnology, Adekunle Ajasin University Akungba Akoko.

ii. Chemicals and Reagents Enzymes: pepsin (from porcine stomach), trypsin (from bovine pancreas), papain

(from Carica papaya), chymotrypsin (human), and alpha-amylase (from saccharomyces cerevisiae) were products
of Kem Light Laboratories, India. alpha-glucosidase (Saccharomyces cerevisiae) and other reagents used were of
analytical grade and were purchased from Sigma Aldrich (USA).

77 6 b) Methods

⁷⁸ 7 i. Isolation of Moringa oleifera seed proteins

The Moringa oleifera seeds were dried and pulverized before being kept in an air-tight container at 4 0 C.This 79 80 were defatted using n-hexane as described by Wani et al., (2011). The meal was extracted four times with nhexane(60-80 o C) using a meal/solvent ratio of 1:10(w/v). The meal was dried at 40 0 C in a vacuum oven 81 and ground again to obtain a fine powder, termed defatted seed meal, which was then stored at -20 0 C.The 82 protein component of the defatted meal was extracted using the method described by Alashi et al., (2014) with 83 modifications. Defatted Moringa seed meal was suspended in 0.5M NaOH pH 12.0 at a ratio of 1:10 and stirred 84 for one hour to facilitate alkaline solubilisation. This was then centrifuged at 18 0 C and 3000g for 10min. Two 85 additional extractions of the residue from the centrifugation process were carried out with the same volume of 86 0.5M NaOH and the supernatants were pooled. The pH of the supernatant was adjusted to pH 4.0 to facilitate 87 acid-induced protein precipitation using 5M HCl solution; the precipitate formed was recovered by centrifugation 88 as described above. Also the pH of the supernatant formed was further adjusted to a pH of 5.5 using 0.1M 89 NaOH. The precipitates formed were recovered by centrifugation. They were then washed with distilled water, 90 91 adjusted to pH using 0.1M NaOH, freeze-dried and the protein isolate was stored at -20 0 C until required for 92 further analysis.

ii. Preparation of Moringa oleifera seed protein Hydrolysates The protein isolate was hydrolysed using the
methods described by Onuh et al.,(2015) with slight modifications. The conditions for hydrolysis were tailored
for each enzyme in order to optimize its activity. Hydrolysis were done using each of pepsin (pH 2.2, 37 0 C),
trypsin (pH 8.0, 37 0 C), papain (pH 6.0, 50 0 C) and chymotrypsin (pH 8.0, 37 0 C). The protein isolate (5%
w/v, based on the protein content of the isolate) was dissolved in the appropriate buffer (phosphate buffer, pH
8.0 for trypsin and chymotrypsin, glycine buffer, pH 2.2 for pepsin, phosphate buffer, pH 6.0 for papain). The
enzyme was added to the slurry at an enzyme-substrate ratio (E: S) of 2:100. Digestion was performed at the

specified conditions for 24 hours with continuous stirring. The enzyme was inactivated by boiling in water bath 100

(95-100 0 C) for 15 minutes followed by centrifugation at 700g for 30 minutes. The supernatant containing target 101

peptides were then collected. Protein content of samples were determined using biuret assay method with bovine 102 serum albumin (BSA) as standard. 103

8 iii. Inhibition of Hemoglobin Glycosylation 104

This was investigated by estimating the degree of non-enzymatic hemoglobin glycosylation according to the 105 method described by Venu, et al., (2016) with modifications. Glucose solution (2%), 0.06% hemoglobin and 106 Gentamycin (0.02%) solution were prepared in phosphate buffer 0.1M, pH 7.4. 1ml each of above solution 107 was mixed. 0.25ml, 0.50ml, 0.75ml and 1ml of hydrolysate was added to above mixture. Gallic acid was used as 108 standard. The mixture was kept in dark at room temperature for incubation for 72hours. At 520nm, haemoglobin 109 glycosylation was measured with a spectrophotometer and % inhibition was calculated thus: 110

Percentage of hemoglobin glycosylation = $Abs(sample) - Abs(control)/Abs(sample) \times 100\%$ 111

iv. Determination of ?-glucosidase Inhibition 9 112

The effect of the hydrolysates on ??-glucosidase activity were determined according to the method described by 113 (Kim et al., 2005) with slight modifications, using ??-glucosidase from Saccharomyces cerevisiae. The substrate 114 solution p-nitrophenyl glucopyranoside (pNPG) was prepared in 20 mM phosphate buffer, and pH 6. pre-115 incubated with 100??L of the different concentrations of the hydrolysates for 10 min. Then 50??L of 3.0 mM 116 (pNPG) as a substrate dissolved in 20 mM phosphate buffer (pH 6.9) will be added to start the reaction. The 117 reaction mixture were incubated at 37 ? C for 20 min and stopped by adding 2mL of 0.1 M Na 2 CO 3 118 solution. The ??-glucosidase activity was determined by measuring the yellow-colored para-nitrophenol released 119 from pNPG at 405 nm. The results were expressed as percentage of the blank control. Percentage inhibition 120 were calculated as:% Inhibition = (Acontrol-Asample) / Acontrol \times 100 v. 121

Determination of Kinetic Parameters of ?glucosidase Inhibi-10122 tion 123

The kinetic parameters of ??-glucosidase by the hydrolysates were determined according to the modified method 124 described by Ali et al., (2006). Briefly, 50??L of the (5 mg/mL) hydrolysate was pre-incubated with 100??Lof 125 ??-glucosidase solution for 10 min at 25?C in one set of tubes. In another set of tubes, ??-glucosidase was 126 pre-incubated with 50??L of phosphate buffer (pH 6.9). 50??L of pNPG at increasing concentrations (0.63-2.0 127 mg/mL) was added to both sets of reaction mixtures to start the reaction. The mixtures were then incubated 128 for 10 min at 25 °C, and 500??L of Na 2 CO 3 solution was added to stop the reaction. The amount of reducing 129 sugars released were determined spectrophoto-metrically at 405nm using a paranitrophenol standard curve and 130 converted to reaction velocities. A double reciprocal plot (1/V versus 1/[??]) where V is reaction velocity and [??] 131 is substrate concentration was then plotted. The mode of inhibition of the hydrolysates on ??-glucosidase activity 132 was determined by analysis of the double reciprocal (Lineweaver-Burk) plot using Michaelis Menten kinetics. 133

vi. Statistical Analysis 11 134

Results were expressed as mean of replicates \pm standard error of mean (SEM). The data were statistically 135 analyzed using One Way Analysis of Variance (ANOVA) and Duncan's multiple range tests. Differences were 136 considered statistically significant at p<0.05 using Microsoft Excel and GraphPad Prism version 7.0 (GraphPad 137 Software, San Diego, CA, USA). 138

III. 12139

Results 13140

a) Inhibition of Haemoglobin Glycosylation 14 141

The effects of Moringa oleifera seed protein hydrolysates on non-enzymatic haemoglobin glycosylation at a 142 concentration range of 0.25mg/ml to 1.00mg/ml are illustrated in Figure 1. The hydrolysates showed a 143 concentration-dependent reduction in the inhibition of hemoglobin glycosylation. Also, they demonstrated 144 145 significantly lower (p<0.05) inhibitory effects when compared to gallic acid. Peptic hydrolysates exhibited inhibitory effect of $62.583\pm0.621\%$ at a final concentration of 1.00 mg/ml, which was significantly (p<0.05) 146 147 higher when compared to other hydrolysates, at the same concentration. Chymotrypsin hydrolysates, with a inhibitory extent of $53.513 \pm 0.361\%$ had higher inhibitory effects than tryptic and papain hydrolysates 148 $(38.360\pm0.439\%$ and $46.540\pm0.323\%$ respectively) while tryptic hydrolysates had lowest inhibitory activity. 149 Figure ?? depicts the IC 50 Values of Moringa oleifera seed protein hydrolysates in inhibiting hemoglobin 150 glycosylation as compared to gallic acid. Peptic hydrolysates inhibited hemoglobin glycosylation to a 50% extent 151 at a concentration of 0.533 ± 0.392 mg/ml, while tryptic, papain and chymotrypsin hydrolysates exhibited 50% 152 inhibition at 0.113±0.027mg/ml, 0.599±0.026mg/ml and 0.765±0.046mg/ml respectively. With the exception of 153

 $_{154}$ tryptic hydrolysates, all the other hydrolysates had significantly (p<0.05) higher IC 50 values when compared to

gallic acid. Hydrolysates derived from tryptic digestion had significantly lower (p<0.05) IC 50 values than other hydolysates, just as values obtained for peptic and papain hydrolysates were not significantly (p<0.05) different

hydolysates, just as values obtained for peptic and papain hydrolysates were 1from each other, but were lower than those of chymotrypsin hydrolysates.

158 15 b) ?-Glucosidase Inhibitory Activity

The inhibitory activities of the hydrolysates on ?-glucosidase -catalyzed hydrolysis of p-nitrophenyl glucopyranoside at varying concentrations are presented in Figure ??. The hydrolysates displayed increasing inhibitory activity with increasing concentration, with peptic, tryptic, papain and chymotryptic hydrolysates attaining 71.040 \pm 6.322%, 80.620 \pm 2.308%, 74.06 \pm 0.081% and 72.39 \pm 0.450% inhibition respectively at a final concentration of 1.0mg/ml. Tryptic hydrolysates demonstrated the highest inhibitory activity at all concentrations in this study(p<0.05). At lower concentrations however, papain hydrolysates had significantly higher (p<0.05) inhibitory activity than peptic and chymotrypsin hydrolysates.

Figure ?? shows the IC 50 values of the four hydrolysates in inhibiting the reaction catalyzed by ?glucosidase. Peptic and tryptic hydrolysates inhibited the reaction to a 50% extent at concentrations of 0.465 ± 0.394 mg/ml and 0.151 ± 0.027 mg/ml respectively, while papain and chymotrypsin hydrolysates had IC 50 values of 3.348 ± 0.028 mg/ml and 0.085 ± 0.013 mg/ml respectively. The IC 50 values of tryptic and chymotrypsin hydrolysates were not significantly (p<0.05) different from each other, but they were lower than those obtained by peptic and papain hydrolysates. Also, peptic hydrolysates had a significantly (p<0.05) lower IC 50 value than

172 papain hydrolysates.

Each bar represents the mean of triplicate determinations \pm SEM. Bars with same letters are not significantly different at (p < 0.05), while bars with different letters are significantly different.

¹⁷⁵ 16 c) Kinetics of ?-glucosidase inhibition

The effects of M. oleifera seed protein hydrolysates on the kinetics of ?-glucosidase-catalyzed hydrolysis of p-176 nitrophenyl glucopyranoside, p-NPG, to p-nitrophenol are illustrated in figures 5-8. The kinetic parameters from 177 the resulting Line-weaver Burk plots are summarized in Table 1. In the absence of inhibitory hydrolysates, the 178 Michaelis constant, k m of ?-glucosidase for its substrate was determined to be 0.297 p-NPG, while maximum 179 velocity, Vmax, was 270.27mM/mg/min. All hydrolysates except papain hydrolysates, caused a concentration 180 dependent increase in the apparent k m of the enzyme. Also, all hydrolysates reduced the maximum velocity, 181 Vmax as well as the catalytic efficiency, CE, of the ?-glucosidase reaction. Hydrolysates from chymotrypsin 182 digestion exhibited the most reduced CE, while peptic hydrolysates displayed the most reduced Vmax, when 183 compared to other hydrolysates. 184

The enzyme-inhibitor dissociation constant, k i , was lowest with chymotryps in hydrolysates (0.193mg/ml), although it was only slightly lower than 0.203mg/ml obtained for tryptic hydrolysates. Papain hydrolysates had the highest k i value of 1.278mg/ml. The mode of inhibition of peptic, tryptic and papain hydrolysates was the mixed type, while chymotrypsin hydrolysates displayed a competitive inhibition of ?glucosidase.

¹⁸⁹ 17 Discussion a) Inhibition of Hemoglobin Glycosylation

The formation of advanced glycation end products (AGEs) as a result of poorly controlled hyperglycemia in 190 diabetes mellitus leads to a plethora of complications such as retinopathy, renal dysfunction atherosclerosis, 191 among other devastating conditions (Ramasamy et al., 2005, Singh et al., 2014). These AGEs cause deleterious 192 effects by promoting the generation of reactive oxygen species which activate a cascade of signaling pathways, 193 leading to an increase in the production of pro-inflammatory mediators, leading to other complications such as 194 the formation of atherosclerotic plaques and culminating in cardiovascular disease in diabetic patients ??Han 195 et al., 2018). Certain plant extracts have been reported to inhibit haemoglobin glycosylation in vitro (Hosseini 196 et al., 2015), but information has been scarce on the abilities of peptides and protein hydrolysates to inhibit 197 haemoglobin glycosylation. In this study, the hydrolysates displayed a concentration dependent reduction in 198 their abilities to inhibit haemoglobin glycosylation in vitro, such that peptic and chymotrypsin hydrolysates had 199 >50% inhibition at a final concentration of 1.00mg/ml, which was higher than those of other hydrolysates. This 200 may be due to the possible influence of the nature of the peptides in the hydrolysate preparations. Chymotrypsin 201 cleaves proteins specifically at C-terminals of aromatic amino acid residues, while pepsin being relatively non-202 specific, hydrolyzes proteins at C-terminals of aminoacyl residues having hydrophobic and aromatic side chains 203 (Voet and Voet, 2011). This may give rise to residues such as Trp, Tyr, Leu, Phe, Ile found at these positions, 204 and as such could be responsible for anti-AGE formation. This is evidenced by the recent report by Han et al., 205 (2014) that Asn-Trp dipeptides inhibited the formation of AGEs in mice models. 206

²⁰⁷ 18 b) ?-Glucosidase Inhibition

208 ?-glucosidase is one of the enzymes found on the brush border membranes of the intestinal mucosa and participates 209 in carbohydrate digestion by hydrolyzing glucose residues from oligosaccharides (Voet and Voet, 2011). Thus, the 210 modulation of the activity of this enzyme represents on key strategy in the control of blood glucose levels in the

management of 1. The Michaelis constant, k m, of ?-glucosidase for p-nitrophenyl glucopyranoside in the absence

of inhibitor was determined to be 0.297mg/ml p-NPG in this study. This is slightly higher than 0.211mg/ml 212 (0.7mM) p-NPG obtained by Awosika and Aluko (2019) and lower than 6.31mg/ml reported by Arise et al., 213 (2019). V max, in the absence of inhibitory hydrolysates was 270.27mM/mg/ml. The Lineweaver Burk plots 214 indicate that hydrolysates derived from peptic digestion displayed a mixed type of inhibition at 0.5mg/ml and 215 an uncompetitive type of inhibition at 1.0 mglml. This partly compares to the uncompetitive mode of inhibition 216 obtained by Arise et al., (2019) for Luffa cylindrica seed protein hydrolysates. Papain hydrolysates on the other 217 hand, showed mixed mode of inhibition at all concentrations. This means that the peptides in the hydrolysate 218 preparations tend to bind and inhibit the ?-glucosidase in both its free form and p-NPG bound forms, creating 219 dead-end complexes. Chymotrypsin and tryptic hydrolysates on the other hand exhibited a competitive type of 220 221 inhibition, which was in contrast to an uncompetitive mode of inhibition for the 1kD fraction of Chymotrypsin hydrolysates derived from yellow field pea proteins as reported by Awosika and Aluko (2019). This could be 222 because the hydrolysates used in this study were unfractionated, thus containing peptides of different lengths 223 and molecular sizes. In addition, the presence of proline, basic and bulky aminoacyl residues in the peptide 224 chains could confer on them, the ability to lock into the enzyme active site (Yu et al., 2011), thereby preventing 225 substrate binding. 226

Maximal rate of reaction, Vmax, as well as catalytic efficiency, CE, of the enzymatic reaction were reduced by the four hydrolysates, which is usually seen with the different modes of inhibition. The enzymeinhibitor dissociation constant, k i, of 0.193mg/ml, 0.203mg/ml and 0.305mg/ml determined for chymotryptic, and peptic and tryptic hydrolysates respectively, and was lower than 10.51mg/ml and 49.83mg/ml obtained for tryptic and peptic hydrolysates Arise et al., (2019) for Luffa cylindrica seed protein hydrolysates. This indicates that hydrolysates derived from chymotrypsin and tryptic digestion showed higher binding affinity for ?-glucosidase when compared to papain hydrolysates.

234 V.

235 **19** Conclusion

To summarize, the hydrolysates derived from enzymatic digestion of M. oleifera seed proteins demonstrated 236 potential anti-diabetic activities in-vitro by inhibiting both the formation of glycosylated haemoglobin and 237 ?-glucosidase activity. Peptic and chymotrypsin hydrolysates displayed better inhibitory effects against non-238 enzymatic glycosylation of haemoglobin, while chymotrypsin and tryptic hydrolysates demonstrated higher ?-239 glucosidase inhibitory properties. This not only justifies the use of M. oleifera seeds for alernative therapeutic 240 purposes, but may also indicate that these proteins could be potential sources of biologically active peptides which 241 could be optimized to formulate new and potent antidiabetic agents. Further studies such as fractionation of 242 these hydrolysates and characterization of resulting peptides responsible for the observed biofunctional properties 243 are suggested, and are currently underway.



Figure 1: B

244



Figure 2: Figure 1 :



Figure 3: Figure 2 :



Figure 4: Figure 4 :BFigure 3 :



Figure 5: Figure 6 : 1 B



Figure 6: Figure 5 : Figure 7 : Figure 8 : B



Figure 7:



Figure 8:

 $\mathbf{1}$

Figure 9: Table 1 :

- [Antimicrobial Profile of Moringa oleifera Lam. Extracts against Some Food -Borne Microorganisms Bayero Journal of Pure and
 Antimicrobial Profile of Moringa oleifera Lam. Extracts against Some Food -Borne Microorganisms Bayero
- Journal of Pure and Applied Sciences 3 (1) p. .
- $_{248}\quad [{\rm Bukar \ et \ al.}\ ()]\ , A \ {\rm Bukar}\ , A \ {\rm Uba}\ , T \ {\rm I}\ {\rm Oyeyi}\ .\ 2010.$
- $_{\rm 249}$ $~[{\rm Voet}~{\rm and}~{\rm Voet}~, {\rm J}~{\rm G}~{\rm Voet}~, {\rm J}~{\rm G}~{\rm Voet}~, {\rm Biochemistry}~2011.$ John Wiley & Sons. (4th ed)
- [Mune-Mune et al. ()] 'A comparison on the nutritional quality of proteins from Moringa oleifera leaves and
 seeds'. M A Mune-Mune , E C Nyobe , C B Bassogog , S R Minka . Cogent Food & Agriculture 2016. 2 p.
 1213618.
- [Singh et al. ()] 'Advanced Glycation End Products and Diabetic Complications'. V P Singh , A Bali , Singh ,
 A S Jaggi . Korean J Physiol Pharmacol 2014. 18 p. .
- [Ramasamy et al. ()] 'Advanced glycation end products and RAGE: a common thread in aging, diabetes,
 neurodegeneration, and inflammation'. R Ramasamy , S J Vannucci , S S Yan , K Herold , S F Yan , A
 M Schmidt . *Glycobiology* 2005. 15 (7) p. .
- [Olusola and Ekun ()] 'Alpha-Amylase -Inhibitory Properties and in vitro Antioxidant Potentials of Cowpea
 Seed Protein Hydrolysates'. A O Olusola , O E Ekun . AASCIT Communications 2019. 6 (1) p. .
- [Ali et al. ()] 'Alpha-amylase inhibitory activity of some Malaysian plants used to treat diabetes, with particular
 reference to Phyllanthus amarus'. H Ali , P J Houghton , A Soumyanath . J. Ethnopharmacol 2006. 107 p. .
- 262 [Wright et al. ()] 'An Investigation of the Antioxidant Capacity in Extracts from Moringa oleifera Plants Grown
- in'. R J Wright , K S Lee , H Hyacinth , J M Hibbert , M E Reid , A O Wheatley , H N Asemota . Jamaica.
 Plants 2017. 6 p. .
- [Han et al. ()] 'Asn-Trp dipeptides improve the oxidative stress and learning dysfunctions in D-galactose-induced
 BALB/ c mice'. C Han , Y Lin , T Lee , H Liang , W Hou . Food and Function 2014. 5 (9) p. .
- [Arise et al. ()] 'b). In vitro antioxidant and -amylase inhibitory properties of watermelon seed protein
 hydrolysates'. R O Arise , A A Yekeen , O E Ekun . *Environmental and Experimental Biology* 2016. 14
 p. .
- [Katzung and Trevor ()] Basic and Clinical Pharmacology, B G Katzung , A J Trevor . 2012. p. . (12 th edition.
 Lange Publishers pp)
- 272 [Garza et al. ()] 'Biofunctional properties of bioactive peptide fractions from protein isolates of moringa seed
- (Moringa oleifera)'. N G Garza , J A Koyoc , J A Castillo , E A Zambrano , D B Ancona , L C Guerrero , S
 R Garcia . J. Food Sci. Technol 2017. p. .
- [Alashi et al. ()] 'Blood pressure lowering effects of Australian canola protein hydrolysates in spontaneously
 hypertensive rats'. A M Alashi , C L Blanchard , R J Mailer , S O Agboola , A J Mawson , R He , S A
 Malomo , A Girgih , R E Aluko . Food Research International 2014. 55 p. .
- [Wani et al. ()] 'Characterisation and Functional Properties of Watermelon (Citrullus lanatus) Seed Proteins'. A
 A Wani , D S Sogi , P Singh , I A Wani , U S Shivhare . J. Agric. Food Chem 2011. 91 p. .
- [Villarruel-López et al. ()] 'Effect of Moringa oleifera consumption on diabetic rats'. A Villarruel-López , D
 A López-De La Mora , O D Vázquez-Paulino , A G Puebla-Mora , M R Torres-Vitela , L R Guerrero Quiroz , K Nuño . 10.1186/s12906-018-2180-2. https://doi.org/10.1186/s12906-018-2180-2 BMC
- 283 Complementary and Alternative Medicine 2018. 18.
- [Qaisar et al. ()] 'Evaluation of ?-glucosidase Inhibitory Activity of Dichoromethane and Methanol Extracts of
 Croton bonpladianum Baill'. M N Qaisar , B A Chaudhary , M U Sajid , N Hussain . Tropical Journal of
 Pharmaceutical Research 2014. 13 (11) p. .
- [Venu et al. ()] 'Evaluation of in vitro antidiabetic activity on ethanolic extract of aerial parts of Murraya
 koenigii: Non-enzymatic glycosylation of hemoglobin'. M R Venu , B P Shanaj , B S Heena , K A Preema ,
- S Mahesh , K Shaik , G Nagarajan . Indian Journal of Research in Pharmacy and Biotechnology 2016. 4 (3) p. .
- [Arise et al. ()] 'In vitro Angiotensin-1-converting enzyme, ?-amylase and ?-glucosidase inhibitory and antiox idant activities of Luffa cylindrical (L.) M. Roem seed protein hydrolysate'. R O Arise , J J Idi , I M
 Mic-Braimoh , E Korode , R N Ahmed , O Osemwegie . *Heliyon* 2019. 7 (5) p. e01634.
- [Awosika and Aluko ()] 'Inhibition of the in-vitro activities of ?-amylase, ?-glucosidase and pancreatic lipase by
 yellow field pea (Pisum satvum L.) protein hydrolysates'. T O Awosika, R E Aluko . 10.1111/ijfs.14087. Int.
 J. Food Sci and Tech 2019.
- [Kim et al. ()] 'Inhibitory effect of pine extract on alpha-glucosidase activity and postprandial hyperglycemia'.
 Y M Kim , Y K Jeong , M H Wang , W Y Lee , H I Rhee . Nutrition 2005. 21 (6) p. .
- [Hosseini et al. ()] 'Inhibitory potential of pure isoflavonoids, red clover, and alfalfa extracts on hemoglobin
 glycosylation'. M Hosseini , S Asgary , S Najafi . ARYA Atheroscler 2015. 11 (2) p. .

- 301 [Onuh et al. ()] 'Kinetics of in vitro renin and angiotensin converting enzyme inhibition by chicken skin protein
- $_{302}$ hydrolysates and their blood pressure lowering effects in spontaneously hypertensive rats'. J O Onuh , A T
- 303 Girgih , S A Malomo , R E Aluko , M Aliani . Journal of functional food 2015. 14 p. .
- [Olusola et al. ()] 'Moringa oleifera Seed Protein Hydrolysates: Kinetics of ?-amylase Inhibition and Antioxidant
 Potentials'. A O Olusola, O E Ekun, T I David, O E Olorunfemi, M B Oyewale. Global Advanced Research
 Journal of Medicine and Medical Sciences 2018. 7 (9) p. .
- [Yu et al. ()] 'Novel Peptides Derived from Egg White Protein Inhibiting Alpha-glucosidase'. Z Yu , Y Yin , W
 Zhao , Y Yu , B Liu , J Liu , F Chen . Food Chemistry 2011. 129 p. .
- 309 [Baptista et al. ()] 'Protein fractionation of seeds of Moringa oleifera Lam and its application in superficial
- 310 water treatment'. A T Baptista , M O Silva , R G Gomes , R Bergamasco , M F Vieira , A M Vieira .
- 311 10.1016/j.seppur.2017.02.040. http://dx.doi.org/10.1016/j.seppur.2017.02.040 Separation and 312 Purification Technology 2017.
- ³¹³ [Arise et al. ()] 'Protein Hydrolysates from Citrullus lanatus Seed: Antiradical and Hydrogen Peroxidescavenging properties and kinetics of Angiotensin-I converting enzyme inhibition'. R O Arise, A A Yekeen,
- O E Ekun, O J Olatomiwa. Ceylon Journal of Science 2016. 45 (2) p. .
- [Madubuike et al. ()] 'Proximate Analysis of Moringa oleifera Seed and Characterization of The Seed Oil'. P C
 Madubuike , D N Nwobu , C C Nwajiobi , D E Ezemokwe . Int. J. Basic and Appl. Sci 2015. 4 (1) p. .
- 318 [Ibrahim et al. ()] 'Structural properties of bioactive peptides with ?-glucosidase inhibitory activity'. M A Ibrahim
- , M Bester , J Neitz , A W Gaspar , AR . Chem Biol. Drug Des 2018. 91 (2) p. .
- [Okereke and Akaninwor ()] 'The protein quality of raw leaf, seed and root of Moringa oleifera grown in Rivers
 State'. C J Okereke , J O Akaninwor . Nigeria. Annals of Biol. Res 2013. 4 (11) p. .
- 322 [Lien and Lowman ()] 'Therapeutic peptides'. S Lien, H Lowman. Trends in Biotechnology 2004. 21 (12) p. .